Literature DB >> 16645217

Rapid one-step carrier detection assay of mucolipidosis IV mutations in the Ashkenazi Jewish population.

Feras M Hantash1, Susan C Olson, Ben Anderson, Arlene Buller, Rebecca Chen, Beryl Crossly, Weimin Sun, Charles M Strom.   

Abstract

Two mutations in the MCOLN1 mucolipidosis IV (ML IV) gene represent approximately 95% of the mutations in Ashkenazi-Jewish patients with ML IV. The mutations, a splice site mutation (IVS3-2A>G) and an approximately 6.4-kb deletion (511del6434), account for 72% and 23% of ML IV alleles in this population, respectively. An automated high-throughput assay was developed using the 5'-nuclease (TaqMan) method for the simultaneous detection of both mutations in a single reaction. Three fluorescent probes specifically detected wild-type, IVS3-2A>G, and 511del6434 alleles in each reaction real-time. Data collected were automatically analyzed, and genotype results were uploaded into a laboratory information management system. The assay was validated using genomic controls, demonstrating high robustness and accuracy. Carrier screening of 10,527 samples revealed 77 heterozygote carriers of IVS3-2A>G, 25 heterozygote carriers of 511del6434, and two compound heterozygote of both mutant alleles. The frequency of mutated alleles was 0.73% for IVS3-2A>G and 0.24% for 511del6434. The combined carrier frequency was 1:103 with predicted disease incidence of 1:42,436 individuals in this population, slightly lower than previously described frequencies. This automated high-throughput assay is labor saving, because two mutations can be detected in a single reaction. The method has potential for use in other assays requiring simultaneous detection of two mutations.

Entities:  

Mesh:

Year:  2006        PMID: 16645217      PMCID: PMC1867596          DOI: 10.2353/jmoldx.2006.050026

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  11 in total

1.  Carrier screening for mucolipidosis type IV in the American Ashkenazi Jewish population.

Authors:  Lisa Edelmann; Jianli Dong; Robert J Desnick; Ruth Kornreich
Journal:  Am J Hum Genet       Date:  2002-02-13       Impact factor: 11.025

2.  Time-motion analysis of 6 cystic fibrosis mutation detection systems.

Authors:  Amy E Krafft; Jack H Lichy
Journal:  Clin Chem       Date:  2005-04-28       Impact factor: 8.327

3.  Mucolipidosis type IV: novel MCOLN1 mutations in Jewish and non-Jewish patients and the frequency of the disease in the Ashkenazi Jewish population.

Authors:  R Bargal; N Avidan; T Olender; E Ben Asher; M Zeigler; A Raas-Rothschild; A Frumkin; O Ben-Yoseph; Y Friedlender; D Lancet; G Bach
Journal:  Hum Mutat       Date:  2001-05       Impact factor: 4.878

4.  Identification of the gene causing mucolipidosis type IV.

Authors:  R Bargal; N Avidan; E Ben-Asher; Z Olender; M Zeigler; A Frumkin; A Raas-Rothschild; G Glusman; D Lancet; G Bach
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

5.  Mucolipidosis IV consists of one complementation group.

Authors:  E Goldin; A Cooney; C R Kaneski; R O Brady; R Schiffmann
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

6.  Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel.

Authors:  M Sun; E Goldin; S Stahl; J L Falardeau; J C Kennedy; J S Acierno; C Bove; C R Kaneski; J Nagle; M C Bromley; M Colman; R Schiffmann; S A Slaugenhaupt
Journal:  Hum Mol Genet       Date:  2000-10-12       Impact factor: 6.150

7.  Molecular screening for diseases frequent in Ashkenazi Jews: lessons learned from more than 100,000 tests performed in a commercial laboratory.

Authors:  Charles M Strom; Beryl Crossley; Joy B Redman; Franklin Quan; Arlene Buller; Matthew J McGinniss; Weimin Sun
Journal:  Genet Med       Date:  2004 May-Jun       Impact factor: 8.822

8.  Mucolipidosis IV: novel mutation and diverse ultrastructural spectrum in the skin.

Authors:  R Bargal; H H Goebel; E Latta; G Bach
Journal:  Neuropediatrics       Date:  2002-08       Impact factor: 1.947

9.  The neurogenetics of mucolipidosis type IV.

Authors:  G Altarescu; M Sun; D F Moore; J A Smith; E A Wiggs; B I Solomon; N J Patronas; K P Frei; S Gupta; C R Kaneski; O W Quarrell; S A Slaugenhaupt; E Goldin; R Schiffmann
Journal:  Neurology       Date:  2002-08-13       Impact factor: 9.910

10.  Cloning of the gene encoding a novel integral membrane protein, mucolipidin-and identification of the two major founder mutations causing mucolipidosis type IV.

Authors:  M T Bassi; M Manzoni; E Monti; M T Pizzo; A Ballabio; G Borsani
Journal:  Am J Hum Genet       Date:  2000-09-29       Impact factor: 11.025

View more
  2 in total

Review 1.  Neuropathophysiology, Genetic Profile, and Clinical Manifestation of Mucolipidosis IV-A Review and Case Series.

Authors:  Aleksandra Jezela-Stanek; Elżbieta Ciara; Karolina M Stepien
Journal:  Int J Mol Sci       Date:  2020-06-26       Impact factor: 5.923

Review 2.  Recent omics technologies and their emerging applications for personalised medicine.

Authors:  Dong-Hyuk Kim; Young-Sook Kim; Nam-Il Son; Chan-Koo Kang; Ah-Ram Kim
Journal:  IET Syst Biol       Date:  2017-06       Impact factor: 1.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.